Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Aug;142(2):320-328.
doi: 10.1378/chest.11-1655.

ADRB2 polymorphisms and budesonide/formoterol responses in COPD

Eugene R Bleecker  1 , Deborah A Meyers  2 , William C Bailey  3 , Anne-Marie Sims  4 , Sarah R Bujac  4 , Mitch Goldman  5 , Ubaldo J Martin  5
Affiliations
Randomized Controlled Trial

ADRB2 polymorphisms and budesonide/formoterol responses in COPD

Eugene R Bleecker et al. Chest. 2012 Aug.

Abstract

Background: Effects of β(2)-adrenergic receptor gene (ADRB2) polymorphism on therapeutic responses to long-acting β(2)-adrenergic agonists have not been evaluated in long-term COPD trials. We aimed to investigate the effects of the ADRB2 Gly16Arg polymorphism on response to formoterol alone or in combination with the inhaled corticosteroid budesonide in patients with COPD.

Methods: Patients ≥ 40 years of age with moderate to very severe COPD from the 12-month trial I (NCT00206167) or the 6-month trial II (NCT00206154) were randomly assigned to bid budesonide/formoterol pressurized metered-dose inhaler (pMDI) 320/9 μg or 160/9 μg, budesonide pMDI 320 μg + formoterol dry powder inhaler 9 μg (trial II), budesonide pMDI 320 μg (trial II), formoterol dry powder inhaler 9 μg, or placebo. The effect of Gly16Arg on predose FEV(1) and 1-h postdose FEV(1), exacerbations, diary variables, and adverse events were analyzed.

Results: No significant interaction between genotype and treatment response was observed for predose (P ≥ .197) or postdose FEV(1) (P ≥ .125) in either pharmacogenetic study (n = 2,866). The number of COPD exacerbations per patient-treatment year was low and similar across genotypes for the active treatment groups (both studies). Percentages of patients with adverse events were similar across Gly16Arg genotype groups for each treatment.

Conclusion: Therapeutic response and tolerability to long-term treatment with formoterol alone or in combination with budesonide was not modified by ADRB2 Gly16Arg genotype in two large independent pharmacogenetic studies in patients with moderate to very severe COPD.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Patient disposition by β2-adrenergic receptor gene (ADRB2) Gly16Arg genotype. A, Study I. B, Study II. aOf the 1,490 patients with DNA samples in study I, genotype data were missing for seven patients; n = 1,483 for genotyped patients. bOf the 1,393 patients in study II, genotype data were missing for 10 patients; n = 1,383 for genotyped patients.
Figure 2.
Figure 2.
Adjusted mean change from baseline (95% CI) in predose FEV1 by treatment and ADRB2 Gly16Arg genotype. A, Study I. B, Study II. BUD = budesonide; DPI = dry powder inhaler; FM = formoterol; LS = least squares; PBO = placebo; pMDI = pressurized metered-dose inhaler. See Figure 1 legend for expansion of other abbreviation.
Figure 3.
Figure 3.
Adjusted mean change from baseline (95% CI) in postdose FEV1 by treatment and ADRB2 Gly16Arg genotype. A, Study I. B, Study II. See Figure 1 and 2 legends for expansion of abbreviations.
Figure 4.
Figure 4.
Number of exacerbations per patient-treatment year by treatment and ADRB2 Gly16Arg genotype. A, Study I. B, Study II. See Figure 1 and 2 legends for expansion of abbreviations.
See this image and copyright information in PMC

References

    1. Matheson MC, Ellis JA, Raven J, Johns DP, Walters EH, Abramson MJ. Beta2-adrenergic receptor polymorphisms are associated with asthma and COPD in adults. J Hum Genet. 2006;51(11):943-951 - PubMed
    1. Israel E, Drazen JM, Liggett SB, et al. ; National Heart, Lung, and Blood Institute’s Asthma Clinical Research Network The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med. 2000;162(1):75-80 - PubMed
    1. Israel E, Chinchilli VM, Ford JG, et al. ; National Heart, Lung, and Blood Institute’s Asthma Clinical Research Network Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet. 2004;364(9444):1505-1512 - PubMed
    1. Taylor DR, Drazen JM, Herbison GP, Yandava CN, Hancox RJ, Town GI. Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax. 2000;55(9):762-767 - PMC - PubMed
    1. Wechsler ME, Lehman E, Lazarus SC, et al. ; National Heart, Lung, and Blood Institute’s Asthma Clinical Research Network beta-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med. 2006;173(5):519-526 - PMC - PubMed

Publication types

MeSH terms

Associated data